Revolution Medicines Inc. (RVMD) has started treating patients in its global Phase 3 clinical study, RASolve 308, evaluating a combination treatment for metastatic lung cancer.

The trial tests the company's investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation.

Phase 3 Study Design And Evaluation

The trial compares zoldonrasib in combination with pembrolizumab and a platinum-based chemotherapy doublet against a placebo paired with the same pembrolizumab and chemotherapy regimen.

Zoldonrasib acts as an investigational, RAS(ON) G12D-selective inhibitor designed to combat RAS-addicted cancers.

Primary And Secondary Trial Endpoints

Researchers set progression-free survival as the primary endpoint for the trial.

Secondary endpoints track overall survival, objective response rate, duration of response, safety, tolerability, and patient-reported outcomes.

Revolution Medicines operates as a global, commercial-stage oncology company dedicated to discovering, developing, and delivering innovative therapies for patients diagnosed with RAS-addicted malignancies.

In April 2025, Revolution Medicines shared new clinical data for zoldonrasib (RMC-9805) as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC).

Zoldonrasib had a favorable mean dose intensity of 98%, and no dose-limiting toxicities were observed.

Preliminary antitumor activity was assessed in 18 efficacy-evaluable patients with NSCLC at the 1200 mg QD dose. The objective response rate (confirmed or pending confirmation) was 61% (n=11), and the disease control rate was 89% (n=16).

RVMD Price Action: Revolution Medicines shares were up 6.90% at $194.71 at the time of publication on Tuesday, according to market data.